STOCK TITAN

MariMed (MRMD) COO details stock trades and RSU payout for 2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc.'s Chief Operating Officer Timothy Shaw reported recent stock transactions. On December 12, 2025 he purchased 45,455 shares of common stock at $0.1071 per share. On December 15, 2025, 81,772 restricted stock units vested and converted into common shares, and 24,001 shares were withheld by the company to satisfy tax withholding obligations at $0.1071 per share.

After these transactions, he directly beneficially owned 9,294,541 shares of MariMed common stock. An additional 2,000,000 shares are held indirectly through the Shaw Family Trust for the benefit of his children, for which he disclaims beneficial ownership, and no restricted stock units remain unvested under the May 23, 2025 grant.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shaw Timothy

(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD, MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 12/12/2025 P 45,455 A $0.1071 9,236,770 D
Common stock 12/15/2025 M 81,772 A $0(1) 9,318,542 D
Common stock 12/15/2025 F 24,001(2) D $0.1071 9,294,541 D
Common stock 2,000,000 I By the Shaw Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 12/15/2025 M 81,772 (4) (4) Common Stock, par value $.001 per share 81,772 $0 0 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. The Reporting Person's spouse is the trustee of the trust and the shares held in the trust are for the benefit of the Reporting Person's children. The trust is an irrevocable trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on May 23, 2025; there were no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Timothy Shaw 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MariMed (MRMD) report for December 2025?

The filing shows that on December 12, 2025, Chief Operating Officer Timothy Shaw purchased 45,455 shares of MariMed common stock at $0.1071 per share. On December 15, 2025, 81,772 restricted stock units vested and converted into common shares, and 24,001 shares were withheld to cover tax withholding obligations.

Who is the reporting person in this MariMed (MRMD) insider filing?

The reporting person is Timothy Shaw, who serves as Chief Operating Officer of MariMed Inc. He filed the report as a single reporting person, indicating his relationship as an officer of the company.

How many MariMed shares does Timothy Shaw own after these transactions?

Following the reported transactions, Timothy Shaw directly beneficially owned 9,294,541 shares of MariMed common stock. An additional 2,000,000 shares are reported as indirectly owned through the Shaw Family Trust.

What happened to Timothy Shaw's restricted stock units (RSUs) in this report?

The report states that 81,772 RSUs converted into shares of common stock on December 15, 2025 on a one-for-one basis. It also notes that these RSUs were part of a grant made on May 23, 2025 and that there were no unvested RSUs remaining under this grant.

Why were 24,001 MariMed shares withheld in connection with the RSU vesting?

The filing explains that the 24,001 shares of common stock were withheld by MariMed to satisfy tax withholding obligations related to the vesting of the restricted stock units.

What is the Shaw Family Trust's role in MariMed (MRMD) share ownership?

The report notes that 2,000,000 shares of MariMed common stock are held by the Shaw Family Trust. Timothy Shaw's spouse is the trustee, the trust is irrevocable, and the shares are for the benefit of their children. Shaw disclaims beneficial ownership of these securities.

Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood